SOBRsafe (SOBR) secures $3.1M via immediate warrant exercise deal
Rhea-AI Filing Summary
SOBR Safe, Inc. entered into definitive agreements for the immediate cash exercise of certain outstanding warrants, with aggregate gross proceeds expected to be approximately $3.1 million before fees and expenses. The warrants relate to up to 2,360,648 shares of common stock originally issued in December 2025 at an exercise price of $1.30 per share and are covered by an effective Form S-1 registration statement.
In consideration for this exercise, the company will issue new unregistered Series E warrants to purchase up to 2,580,648 shares and new unregistered Series F warrants to purchase up to 2,140,648 shares, each with a $1.30 exercise price and immediate exercisability. The Series E warrants will expire five years after the effective date of a planned resale registration statement, and the Series F warrants will expire twenty-four months after that effective date. The transaction is expected to close on or about July 16, 2026, subject to customary closing conditions, and net proceeds are intended for working capital and general corporate purposes.
Positive
- None.
Negative
- None.
Key Figures
Gross Proceeds: $3.1 million
Original Warrants Shares: 2,360,648 shares
Exercise Price: $1.30 per share
+4 more
7 metrics
Gross Proceeds
$3.1 million
Expected aggregate gross proceeds from immediate warrant exercises before fees and expenses
Original Warrants Shares
2,360,648 shares
Shares underlying certain outstanding warrants originally issued in December 2025 at $1.30
Exercise Price
$1.30 per share
Exercise price for original warrants and new Series E and Series F warrants
Series E Warrant Shares
2,580,648 shares
Maximum shares of common stock purchasable under new unregistered Series E warrants
Series F Warrant Shares
2,140,648 shares
Maximum shares of common stock purchasable under new unregistered Series F warrants
Series E Expiration
5 years
Series E warrants expire five years after effective date of the Resale Registration Statement
Series F Expiration
24 months
Series F warrants expire twenty-four months after effective date of the Resale Registration Statement
Key Terms
warrants, private placement, Resale Registration Statement, gross proceeds, +1 more
5 terms
warrants financial
"immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,360,648 shares"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
private placement financial
"The new warrants described above were offered in a private placement pursuant to an applicable exemption"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Resale Registration Statement regulatory
"will expire five years after the effective date of the Resale Registration Statement"
A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.
gross proceeds financial
"The aggregate gross proceeds to the Company from the offering are expected to be approximately $3.1 million"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
transdermal technical
"SOBRsafe’s advanced transdermal (touch-based) technology detects and reports in real-time"
Transdermal describes a method of delivering a drug through the skin so the active ingredient is absorbed into the bloodstream, commonly via a patch, gel or cream. For investors, transdermal delivery affects a product’s convenience, steady dosing, patent and regulatory profile, manufacturing needs and market appeal—similar to a slow-release battery that makes a device easier to use and last longer, which can influence sales potential and risk.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What capital raise did SOBRsafe (SOBR) announce in this 8-K?
SOBRsafe entered agreements for the immediate exercise of certain outstanding warrants, expecting approximately $3.1 million in gross proceeds. The transaction involves cash exercises of warrants originally issued in December 2025 at $1.30 per share.
What are the key terms of SOBRsafe (SOBR) new Series E warrants?
The new Series E warrants allow purchases of up to 2,580,648 shares of common stock at $1.30 per share. They are immediately exercisable and will expire five years after the effective date of the related Resale Registration Statement.
What are the key terms of SOBRsafe (SOBR) new Series F warrants?
The new Series F warrants permit purchases of up to 2,140,648 shares at an exercise price of $1.30 per share. They are immediately exercisable and will expire twenty-four months after the Resale Registration Statement becomes effective.
How does SOBRsafe (SOBR) plan to use the proceeds from the warrant exercises?
SOBRsafe intends to use the net proceeds from the approximately $3.1 million in gross proceeds for working capital and general corporate purposes, providing additional funding for its ongoing operations and business activities.
Are SOBRsafe (SOBR) new Series E and F warrants registered with the SEC?
The new Series E and Series F warrants are unregistered and issued via a private placement under an exemption. SOBRsafe has agreed to file a Resale Registration Statement covering the shares of common stock issuable upon exercise of these new warrants.
When is SOBRsafe (SOBR) expecting the warrant exercise transaction to close?
The warrant exercise and related issuance of new warrants are expected to close on or about July 16, 2026, subject to the satisfaction of customary closing conditions applicable to this type of securities transaction.